Why Protalix BioTherapeutics Plunged

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Protalix BioTherapeutics (NYSE: PLX  ) plunged today by as much as 20% after the company and Pfizer (NYSE: PFE  ) jointly announced that the European Medicines Agency, or EMA, opposed marketing of the company's drug for treating Gaucher disease.

So what: Regulators gave the drug a positive risk-benefit assessment, saying that the benefits of the medicine outweighed the risks in treating Type 1 Gaucher disease. However, the agency could not recommend marketing authorization because another company's competing drug has marketing exclusivity in the European Union for 10 years from the time of its authorization in 2010.

Now what: Protalix and Pfizer are disappointed by the decision, but the silver lining is that the agency assigned a positive risk-benefit assessment and the subsequent overall recommendation was not related to the safety or efficacy profile of the drug in question. The two companies entered into an agreement in 2009 to develop and commercialize the drug. It was approved domestically by the FDA in May.

Interested in more info on Protalix BioTherapeutics? Add it to your watchlist by clicking here.

Fool contributor Evan Niu holds no position in any company mentioned. Click here to see his holdings and a short bio. Motley Fool newsletter services have recommended buying shares of Pfizer. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.


Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 22, 2012, at 4:06 PM, soho48 wrote:

    Doesn't this just mean that PLX will not get royalties from PFE? The number of patients in Europe is not much, so the lost revenue is very little. Most patients are in Israel where approval is pending and this is not shared with PFE. PFE gave PLX 25 million for a milestone payment. Your article is a rehash of the PR, you didnt bring anything new in it.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1921720, ~/Articles/ArticleHandler.aspx, 9/1/2014 9:41:15 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Apple's next smart device (warning, it may shock you

Apple recently recruited a secret-development "dream team" to guarantee its newest smart device was kept hidden from the public for as long as possible. But the secret is out. In fact, ABI Research predicts 485 million of this type of device will be sold per year. But one small company makes Apple's gadget possible. And its stock price has nearly unlimited room to run for early-in-the-know investors. To be one of them, and see Apple's newest smart gizmo, just click here!


Advertisement